From Harvard Medical School; Department of Psychiatry (Drs. Koire and Joffe), Connors Center for Women's Health and Gender Biology (Dr. Joffe), and Center for Alzheimer Research and Treatment, Department of Neurology (Dr. Buckley), Brigham and Women's Hospital, Boston, MA; Department of Neurology, Massachusetts General Hospital, Boston, MA (Dr. Buckley); Melbourne School of Psychological Science and Florey Institutes, University of Melbourne (Dr. Buckley).
Harv Rev Psychiatry. 2022;30(4):215-225. doi: 10.1097/HRP.0000000000000339. Epub 2022 May 26.
After participating in this activity, learners should be better able to:• Outline the clinical recommendations for menopausal hormone treatment related to cognitive concerns• Debate and discuss the various research pieces on the use of menopausal hormone therapy cognitive decline, dysfunction, and dementia.
Menopause has been associated with subjective cognitive dysfunction and elevated rates of depression. While menopausal hormone therapy (MHT) is Food and Drug Administration-approved for the treatment of vasomotor symptoms related to menopause, a potential role for MHT in treating and preventing cognitive decline, dysfunction, and dementia has remained unclear and a topic of continued interest and debate across decades of research. Increasing numbers of patients are seeking help for subjective cognitive decline, and those with poorer mental health are substantially more likely to perceive themselves to be at high risk of developing dementia; thus, mental health professionals are likely to encounter such patients and may be asked to provide advice concerning MHT, cognition, and indications for MHT use. Here, we synthesize the neurobiological effects of MHT, make recommendations for its use in current clinical practice in the contexts of cognitive dysfunction associated with major depressive disorder, cognitive decline, and Alzheimer's disease, and discuss the frontiers being explored by ongoing research on this topic. We conclude that MHT to improve cognitive functioning has only a few scenarios where it would be recommended and that particular caution may be warranted for carriers of the APOE ε4 allele.
在参与此活动后,学习者应能够:
概述与认知问题相关的更年期激素治疗的临床建议
辩论和讨论关于使用更年期激素治疗认知功能减退、障碍和痴呆的各种研究。
更年期与主观认知功能障碍和抑郁发生率升高有关。虽然更年期激素治疗(MHT)已获美国食品和药物管理局批准用于治疗与更年期相关的血管舒缩症状,但 MHT 在治疗和预防认知功能减退、障碍和痴呆方面的潜在作用仍不清楚,并且是几十年来研究的一个持续关注和争论的话题。越来越多的患者正在寻求治疗主观认知减退的方法,而心理健康状况较差的患者更有可能认为自己处于患痴呆症的高风险中;因此,心理健康专业人员可能会遇到这样的患者,并可能被要求就 MHT、认知和 MHT 使用的适应症提供建议。在这里,我们综合了 MHT 的神经生物学效应,针对与重度抑郁症、认知衰退和阿尔茨海默病相关的认知功能障碍、MHT 的使用提出了建议,并讨论了该主题正在探索的前沿领域。我们的结论是,MHT 改善认知功能的情况只有少数几种情况会被推荐,对于携带 APOE ε4 等位基因的患者可能需要特别谨慎。